Concepedia

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

Yan Huang, Min Qi, Cheng-Jin Liao, Jinrui Xun, Ju Zou, Haiyue Huang, Liyuan Long, Jun Chen, Xuegong Fan, Ruochan Chen

Infectious Diseases and Therapy · 2021 · 10 citations · 20 references

DOIFull text

Open access

Abstract

Short PEG-IFNα2b therapy in IHCs produced a high functional cure rate and good safety profile, suggesting that PEG-IFNα2b treatment may be the best choice for clinical cure of some IHCs.

References

20

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Christina Fitzmaurice, Christine A. Allen, Ryan M Barber et al. · JAMA Oncology · 2016 · 6.2K citations · Full text

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · Hepatology · 2018 · 4.1K citations · Full text

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Shiv Kumar Sarin, Manoj Kumar, George Lau et al. · Hepatology International · 2015 · 2.5K citations · Full text

, , +16

Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma

Hwai‐I Yang, Sheng‐Nan Lu, Yun‐Fan Liaw et al. · New England Journal of Medicine · 2002 · 1.2K citations

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B

Yao-Shih Hsu, Rong‐Nan Chien, Chau‐Ting Yeh et al. · Hepatology · 2002 · 708 citations · Full text